Sub-Retinal Administration of OCU400-301 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-02-12 in 4mo
ESTIMATED |
READOUT
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Phase 3 · Retinitis Pigmentosa |
OCGN Ocugen, Inc. | Sub-Retinal Administration of OCU400-301 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-14
Sponsor-projected date — can change
|